Emergent BioSolutions (FRA:ER4) Total Long-Term Liabilities : €704.4 Mil (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Emergent BioSolutions's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €704.4 Mil.

Emergent BioSolutions Total Long-Term Liabilities Historical Data

The historical data trend for Emergent BioSolutions's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Total Long-Term Liabilities Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

864.50

860.40

518.92

479.22

711.00

Emergent BioSolutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial															468.74	471.47	666.29	711.00	704.39

Emergent BioSolutions Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Emergent BioSolutions Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (FRA:ER4) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EBS:USA 0IGA:UK ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines